Related references
Note: Only part of the references are listed.Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review
Xia Guo et al.
CLINICAL DRUG INVESTIGATION (2016)
Text Message Support for Weight Loss in Patients With Prediabetes: A Randomized Clinical Trial. Diabetes Care 2016;39:1364-1370
Mohsen Afarideh et al.
DIABETES CARE (2016)
Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371-1377 RESPONSE
Ryan T. Crews et al.
DIABETES CARE (2016)
Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
Rose A. Gubitosi-Klug et al.
DIABETES CARE (2016)
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Thomas Fremming Dejgaard et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Type 1 Diabetes Treatment Beyond Insulin
Lindsay B. Harrison et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2016)
GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach
Isabella Crisci et al.
ACTA DIABETOLOGICA (2015)
Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study
Reimar Wernich Thomsen et al.
DIABETES CARE (2015)
Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
Christian S. Frandsen et al.
DIABETES CARE (2015)
Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
Feng Sun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies
T. Wang et al.
DIABETES OBESITY & METABOLISM (2015)
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes
Benjamin Udoka Nwosu et al.
PLOS ONE (2015)
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
Bruce A. Perkins et al.
PLOS ONE (2015)
Once-Weekly Exenatide as Adjunct Treatment of Type 1 Diabetes Mellitus in Patients Receiving Continuous Subcutaneous Insulin Infusion Therapy
Andrea N. Traina et al.
CANADIAN JOURNAL OF DIABETES (2014)
Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
Tara Ghazi et al.
DIABETES CARE (2014)
Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
Gayatri Sarkar et al.
DIABETES CARE (2014)
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
David M. Nathan
DIABETES CARE (2014)
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study
K. V. S. Hari Kumar et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2013)
LIRAGLUTIDE AS ADDITIONAL TREATMENT TO INSULIN IN OBESE PATIENTS WITH TYPE 1 DIABETES MELLITUS
Nitesh D. Kuhadiya et al.
ENDOCRINE PRACTICE (2013)
Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
Urd Kielgast et al.
DIABETES (2011)
Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
Urd Kielgast et al.
DIABETES CARE (2011)
Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial
S. L. Ellis et al.
DIABETIC MEDICINE (2011)
Liraglutide as additional treatment for type 1 diabetes
Ajay Varanasi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
Vandana S. Raman et al.
DIABETES CARE (2010)
Temporal patterns in overweight and obesity in Type 1 diabetes
B. Conway et al.
DIABETIC MEDICINE (2010)
Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes
Kristina I. Rother et al.
DIABETES CARE (2009)
Exenatide-Associated Ischemic Renal Failure
W. J. Weise et al.
DIABETES CARE (2009)
Exenatide may aggravate moderate diabetic renal impairment: a case report
Odd Erik Johansen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being
R. J. Moon et al.
DIABETES OBESITY & METABOLISM (2007)
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial
RE Ratner et al.
DIABETIC MEDICINE (2004)
Share Paper
